Gut microbiome boosts muscle strength
Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1462 entries already.
Entries by Thomas Gabrielczyk
Curetis lower respiratory tract panel ready for FDA clearance
/in News/by Thomas GabrielczykMolecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
/in News/by Thomas GabrielczykMerck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal
/in News/by Thomas GabrielczykBoehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and […]
Smart bra set to detect breast cancer
/in News/by Thomas GabrielczykA French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.
GARDP wants five AMR breakers by 2025
/in News/by Thomas GabrielczykGARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.
Sanifit raise 72.2m to push SNF472 development
/in News/by Thomas GabrielczykSanifit has bagged 72.2m in Spains largest private biotech fundraise.
Genfit in $228m deal with Terns Pharmaceuticals
/in News/by Thomas GabrielczykGenfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Vesalius Biocapital III Fund closes at 120 million
/in News/by Thomas GabrielczykLife sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at 120m.
Erytech Pharma SA bags US$57m from SQZ Biotechnologies
/in News/by Thomas GabrielczykErytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.